Approval · Notice of Compliance 36821 · 2026
KEYTRUDA: Notice of Compliance 36821
Issued February 3, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36821
- Date
- February 3, 2026
- Company
- Merck Canada IncKirkland, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New dosage form. Additional manufacturing sites.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| KEYTRUDA | Not yet assigned | — |
| KEYTRUDA SC | 02565382 | Marketed |
Medicinal ingredients
- PEMBROLIZUMAB 25 MG per ML
- PEMBROLIZUMAB 165 MG per ML